Daily Archives: September 3, 2019

Taconic Biosciences Participates in Second Rodent Research Reference Mission to the International Space Station

Resulting Studies Will Provide Critical Reference Data to Drive Advancements in Human Health

RENSSELAER, N.Y., Sept. 03, 2019 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing genetically engineered animal model solutions, announces its participation in the second Rodent Research Reference mission to the International Space Station.

Taconic has a history with NASA dating back to 1985. While previous NASA programs were collaborations with academic and/or commercial organizations to study a particular biological function to advance their own research, the RRR missions are agnostic. This project represents a direct collaboration between the International Space Station (ISS) National Lab, National Aeronautics and Space Administration (NASA), Bioserve Space Technologies with support from the Leidos Corporation, and Taconic. These research models are not tied to a specific study, but rather provide critical reference data to researchers beyond the space program, expanding their impact. ISS and Taconic solicited requests for proposals (RFPs) in March 2019 seeking scientists who would like to access the specimens from this mission.

On July 27, the SpaceX Falcon rocket launched the Dragon spacecraft carrying 40 Taconic C57BL/6NTac mice to the ISS for the second Rodent Research Reference mission (RRR-2). The July mission expands upon a previous mission (RRR-1); which evaluated the general microgravity effects on mice health at two discrete ages. RRR-1 utilized the genetically inbred mice strain, BALB/cAnNTac. Researchers can now compare results from the two strains to gain insight as to which provides the best translational data, enhancing the ability to predict clinical success of future therapies.

The Dragon spacecraft and the mice returned to earth on August 29. Once the mice are safely transported to the lab, specimens will be collected and distributed to the participating researchers.

“Taconic’s mission is to provide researchers with the best animal model solutions to accelerate advancements in human health. Our partnership with the ISS U.S. National Laboratory supports this by providing broad access to critical reference data from the microgravity environment,” shared Dr. John Couse, vice president of scientific services at Taconic. “Scientists will gain a better understanding of the physiological, cellular, and molecular responses to this variable, helping to solve an ongoing problem of identifying the right disease models to drive new drug discovery.”

To learn more about how Taconic’s animal model solutions can progress your research, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immune-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Teledyne e2v announces new CMOS Sensor Family, targeted at 3D Laser Triangulation Applications

Teledyne e2v/CMOS sensor family

New Flash CMOS sensor ideal for laser profiling/displacement applications

GRENOBLE, France, Sept. 03, 2019 (GLOBE NEWSWIRE) — Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, announces its Flash CMOS image sensor family, specifically tailored for 3D laser profiling/displacement applications and high speed, high resolution inspection.

The new Flash sensors feature a 6μm CMOS global shutter pixel which effectively combines high resolution and fast frame rate. They are available in a 4k or 2k horizontal resolution, with respective frame rates of 1800fps and 1500fps (8 bits), and respective readout speeds of 61.4Gbps and 25.6Gbps (the best Gbps/price ratio in the market). The sensors come in a µPGA ceramic package fitting in standard optical formats, APS-like optics in the 4k and C-Mount in the 2k.

Designed to enable easy and cost-effective integration for camera makers, the new sensors include a wide range of application-based features including:

  • High Dynamic Range modes with up to 100dB that enables both the measurement and inspection of highly-reflective surfaces and dark areas in the same image
  • Multiple Region of Interest mode that provides the ideal tradeoff between profiling rate and range/resolution in the height measurement
  • Frame to frame ‘hot’ changes mode of some parameters (exposure time, binning, ROI, flipping and conversion time) that enables flexibility and real-time adaptation to the environment conditions
  • Different trigger modes that allow customers to adapt, depending on the speed of production lines

Flash image sensors are available with a wide range of derivatives at sensor level, so that customers can differentiate to meet specific applications challenges. Examples include, multiple operating modes which trade-off between frame rate, power consumption and the number of bits, increasing frame rate by utilizing horizontal binning and the capability to optimally fit the Scheimpflug angle required for your specific application.

Yoann Lochardet, Marketing Manager for 3D at Teledyne e2v said, “We are very pleased to announce the release of the new Flash family of CMOS sensors which were developed after listening closely to the requirements of leading companies in the market. These new sensors feature a unique set of characteristics targeted at 3D laser triangulation applications including; high resolution, very high frame rate, very high readout speed, HDR capability and a large set of additional features. All these capabilities allow our customers to solve the most challenging application demands in 3D laser profiling/displacement such as quality control and 3D measurement.”

Evaluation Kits and samples of Flash 2K and Flash 4K are now available. Please visit the product page or contact us for more information.

For media enquiries, please contact:
Jessica.Broom@teledyne.com | + 44 (0)1245 453607

Notes to Editors:
About Teledyne e2v
Teledyne e2v is part of the Teledyne Imaging Group. Their innovations lead developments in healthcare, life sciences, space, transportation, defence and security and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of customers and partnering with them to provide innovative standard, semi-custom or fully-custom imaging solutions, bringing increased value to their systems. For more information  imaging.teledyne-e2v.com

About Teledyne Imaging
Teledyne Imaging is a group of leading-edge technology companies aligned within the Teledyne brand. With unrivalled expertise across the electromagnetic spectrum and decades of experience, the group offers world-leading capabilities in sensing, signal generation and processing. The collective delivers innovative solutions to aerospace, defense, geospatial, machine and industrial vision, medical and life sciences, semiconductors and MEMs. For more information, visit teledyneimaging.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d239b0-83eb-4c40-91cd-ec9be0d27603

A view into SNOMED CT’s globally recognized clinical terminology with the release of SNOMED International’s Global Patient Set

London, United Kingdom, Sept. 03, 2019 (GLOBE NEWSWIRE) — Picture an elderly patient navigating orthopaedic care across primary, acute and rehabilitative sectors; a woman moving through breast cancer diagnosis and treatment in a developing digital health environment; or gathering critical patient information in the midst of a conflict, epidemic or disaster. These scenarios represent instances in which the Global Patient Set (GPS) can make an impact in non-SNOMED CT enabled countries.

A slice of SNOMED CT, the GPS is a managed collection of existing reference sets, available to any user at no cost.  The GPS offers clinical content across dentistry, renal, family & general practice and nursing areas, and includes IHE, DICOM and HL7 International Patient Summary (IPS) domains and activities.  SNOMED International’s General Assembly Chair, Lies van Gennip, is encouraged by what the GPS represents, including easier specification of EHR requirements through clinical documents such as a patient summary. Van Gennip shares, “The GPS is a step towards increased clinical information sharing across borders, bridging the interoperability divide through the use of structured terminology.”

Those not presently engaged in SNOMED International membership or party to an affiliate license have the most to gain from the GPS.  The GPS can support the nascent use of clinical terminology within a developing health system, the sharing of patient summary information across borders with existing SNOMED International Member countries or affiliates, as well as promoting use in specification development and research. CEO Don Sweete offers, “The impetus driving the GPS is to introduce a facet of SNOMED CT’s global terminology where it can be put to good use, whether that’s supporting cross border interoperability or enhancing digital maturity.”  SNOMED International has elaborated on these use cases, or scenarios, and has made them openly available.

The GPS contains SNOMED CT unique identifiers, fully specified names, preferred terms in international English, and status flags.  While valuable in many ways to various healthcare actors and their supporting digital environments, it’s important to note that the GPS as a whole is not a clinically curated list; it excludes SNOMED CT’s inherent relationships and hierarchies; fundamental to the nature of an ontology and its ability to enable clinical data analytics, decision support, and power artificial intelligence, etc.  The complete set of concept synonyms and definitions are also not part of the GPS.

Chief among the benefits of SNOMED International membership includes access to terminology that enables interoperability, reduced clinical risk, large scale public health reporting and research, and a wealth of organization resources including education, tooling, creation of national extensions, representation on governance bodies, and dedicated on-boarding and user support.

Offered under the Creative Commons Attribution 4.0 International Public License, the GPS is available to any interested party, at no cost, simply by visiting SNOMED International’s GPS information page and registering your use. The GPS will be updated and released annually to reflect changes to the underlying terminology, including concept inactivations and additions. Implementation guidance has been created and can be found as part of the GPS file as well as on SNOMED International’s GPS information page.

For more information on this exciting product, contact gps@snomed.org.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, theworld’s most comprehensive healthcare terminology product. We play an essential role inimproving the health of humankind by determining standards for a codified language thatrepresents groups of clinical terms. This enables healthcare information to be exchangedglobally for the benefit of patients and other stakeholders. We are committed to the rigorousevolution of our products and services, to deliver continuous innovation for the global healthcarecommunity. SNOMED International is the trading name of the International Health TerminologyStandards Development Organisation

Attachment

Kelly Kuru, Executive Lead, Communications
SNOMED International
1 416 566 8725
kku@snomed.org

Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics

Leiden, 3 September 2019 – Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC) and IDBiologics, a company which focuses on developing human antibodies for the prevention, treatment and cure of infectious diseases.

The Zika virus neutralizing antibody was discovered three years ago by VUMC researchers in collaboration with colleagues at Washington University School of Medicine in St. Louis. The group reported isolation of a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. The VUMC antibody, dubbed ZIKV-117, binds to an epitope or “part of” the Zika virus in a way that no other antibody has to date.

“We’re excited to work with Batavia to move this promising Zika antibody therapy one step closer to the clinic,” stated James Crowe Jr, M.D., Director of the Vanderbilt Vaccine Center.

Developing high yield antibody producer CHO lines is difficult and expensive,” added Robert Carnahan, Ph.D., Director of Vanderbilt Antibody and Protein Resource. “That is why this new solution is so important to the anti-Zika antibody project.”

The mosquito-borne Zika virus is believed to cause microcephaly (unusually small heads) and other congenital malformations in children born to infected women. Currently, there is no way to prevent Zika virus infection or its aftermath.

Menzo Havenga, CEO, Batavia Biosciences, explained: “We are thrilled to now have access to Horizon’s expression system to complement our existing STEP® technology for recombinant protein production and to have VUMC and IDBiologics as collaborators on the development of a much needed Zika virus medical countermeasure.”

Chuck Haines, CEO, IDBiologics commented: “We are looking forward with great anticipation to receiving the Zika virus antibody cell line from the VUMC-Batavia collaboration and continuing to advance this product to the clinic.”

Horizon licenses its CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations. The system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc.. Dirk Gewert, Business Unit Director, Horizon Discovery explained: “This proprietary solution has now been featured in a number of confirmed Investigational New Drug (IND) filings. This solution allows companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible. Both Horizon and Batavia are dedicated to ensure availability of key technologies that can improve affordability of medicines worldwide.

About Batavia Biosciences
Batavia Biosciences significantly contributes to ease human suffering from infectious diseases by improving the success rate in the translation of candidate medicines from discovery to the clinic. We offer our novel technologies and in-depth know-how in order to help our partners to complete preclinical phases in biopharmaceutical product development at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including cell line generation, upstream process development (mammalian & microbial), purification development, product characterization and clinical manufacturing. Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide.

www.bataviabiosciences.com

About Horizon Discovery

Horizon Discovery Group plc (LSE: HZD) (“Horizon”) drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.

Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.

Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.

The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the company to focus efforts on development of innovative solutions that not only differentiate the company’s offering, but also fuel development of the next wave of precision medicines.

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange’s AIM market under the ticker HZD.

www.horizondiscovery.com

About Vanderbilt University Medical Center

Vanderbilt University Medical Center (VUMC) is one of the United States leading academic medical centers and is home to the largest comprehensive health system in the state of Tennessee. Its core missions are the delivery of patient care, performing biomedical research and training future leaders in healthcare. VUMC, which is also home to the Vanderbilt University School of Medicine, is one of the top 10 recipients in the U.S. in total research funding from the National Institutes of Health. In its most recent fiscal year, VUMC experienced more than 2.3 million patient encounters and provided $711 million in charity care and other community benefits to persons in Middle Tennessee. For more information and the latest news follow VUMC on Facebook, LinkedIn, Twitter, and in the VUMC Reporter. 

ww2.mc.vanderbilt.edu

About IDBiologics

IDBiologics develops biologics as therapies or preventative medicines to combat infectious diseases. IDBiologics is a biotech spin out from the laboratory of Dr. James Crowe of Vanderbilt University Medical Center (VUMC). IDBiologics collaborates with the Crowe lab (Nashville, TN), one of the world’s leading monoclonal antibody discovery laboratories, to derive monoclonal antibodies from human donors, optimize their genetic sequence for enhanced performance and safety, and establish proof of concept in relevant animal models of disease. IDBiologics is currently working on preclinical development for three leading candidates addressing significant unmet needs including: Respiratory Syncytial Virus (RSV), Influenza virus (Flu), and Zika virus. IDBiologics is headquartered in Nashville, TN.

www.idbiologics.com

Contact for editors
Menzo Havenga, CEO
m.havenga@bataviabiosciences.com
+31889950600

Attachment

Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) — Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant infections, today announced four upcoming presentations at the ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, taking place September 3-6 in Boston, MA at the Boston Park Plaza. The company and its collaborators will deliver presentations on its lead drug enmetazobactam (formerly AAI101), a potent extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime is currently in late stage of a global Phase 3 development for the treatment of complicated urinary tract infections, including acute pyelonephritis, by Gram-negative bacteria.

“We are excited to share data from four posters at ASM/ESCMID this year. Each of these presentations adds to the growing body of evidence in favor of cefepime-enmetazobactam to treat infections by third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, the most prevalent ‘critical priority’ pathogen as defined by the WHO,” said Klaus Wilgenbus, Chief Executive Officer of Allecra Therapeutics. “These presentations underline our ongoing commitment to make Allecra’s data accessible to practicing physicians.” Third-generation cephalosporin resistance is frequently encountered in Gram-negative hospital pathogens and is mainly mediated by ESBLs. Cefepime-enmetazobactam is intended as an empiric carbapenem-sparing option for the treatment of serious Gram-negative infections in settings where ESBLs are prevalent.

Details for the poster presentations at ASM/ESCMID 2019 are as follows

  • Presentation title: The Exposure‐Response Relationship of Enmetazobactam, Combined with Cefepime, Is Best Described by fT > CT in a Murine Thigh Infection Model
    Authors: F. Bernhard, M. Machacek, P. Warn, R. Odedra, S. Sordello, A. Belley, P. Knechtle
    Date and time: Thursday September 05, 2019 04:30 p.m. – 06:30 p.m.
    Location: Paper Poster Arena, Presentation number P04
  • Presentation title: Pharmacodynamic Targets of Enmetazobactam, Combined with Cefepime, Against ESBL‐Producing Isolates of K. pneumoniae in a Murine Thigh Infection Model
    Authors: P. Warn, R. Odedra, S. Sordello, F. Bernhard, M. Machacek, A. Belley, P. Knechtle
    Date and time: Thursday September 05, 2019 04:30 p.m. – 06:30 p.m.
    Location: Paper Poster Arena, Presentation number P05
  • Presentation title: The Novel β‐lactamase Inhibitor Enmetazobactam is More Potent than Tazobactam against ESBL‐producing Enterobacteriaceae
    Authors: A. Belley, I. Morrissey, S. Hawser, M. Huband, S. Bajaksouzian, M.R. Jacobs, K. Papp‐Wallace, R. A. Bonomo, P. Knechtle
    Date and time: Thursday September 05, 2019 04:30 p.m. – 06:30 p.m.
    Location: Paper Poster Arena, Presentation number P38
  • Presentation title: Pharmacokinetic and Pharmacodynamic Analysis of Cefepime and AAI101 Against Multidrug‐Resistant Enterobacteriaceae
    Authors: A. Johnson, N. Farrington, L. McEntee, P. Knechtle, S. Biondi, S. Shapiro, S. Das, W. Hope
    Date and time: Thursday September 05, 2019 04:30 p.m. – 06:30 p.m.
    Location: Paper Poster Arena, Presentation number P14

These abstracts can be accessed through the ASM/ESCMID website. Following the meeting, the posters will be available on the company website.

About Allecra Therapeutics

Allecra Therapeutics, established in 2013, is a clinical-stage biopharmaceutical company contributing towards the global effort to combat antibiotic resistance by developing new therapeutic modalities to overcome emergent resistance mechanisms, thereby saving lives of patients whose infections may otherwise be treated inadequately.

Allecra’s lead product enmetazobactam (formerly AAI101), in combination with the 4th generation cephalosporin cefepime, is being developed for empiric use in complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP). Cefepime-enmetazobactam holds Qualified Infectious Disease Product (QIDP) status and has been granted Fast Track designation by the FDA.

Allecra is supported by Forbion, Delos Capital, Andera Partners, formerly EdRIP, Xeraya Capital, EMBL Ventures, and BioMed Partners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from the French public bank Bpifrance and from the Région Alsace.

For more information on Allecra please visit www.allecra.com or email IR@allecra.com.

CNH Industrial acquires AgDNA, a leader in Farm Management Information Systems

London, September 3, 2019

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI), today announced its agreement to acquire AgDNA, a leader in Farm Management Information Systems (FMIS). This acquisition will enable CNH Industrial’s customers, and those of third party agricultural machinery, to benefit from AgDNA’s single point data integration, mapping and analytical tools. Paired with CNH Industrial’s agricultural brands’ fleet management telematics, the combined solution will empower farmers and agribusinesses to consolidate a wide range of agronomic data streams, arising from a range of inputs such as machine, agronomic and third party data – including crop prices and weather information – into a single platform, to facilitate expedited decision making. As this open platform works across data sources and brands, it effectively standardizes all data inputs, making it possible for mixed fleet owners to view all data in a uniform manner in one place.

In line with CNH Industrial’s longstanding approach to data control, farmers will continue to control all data utilized by the system as well as maintaining the ability to use the variety of in-house and third-party applications that best suit their farming operation. Furthermore, the acquisition of AgDNA complements CNH Industrial’s existing range of precision farming software solutions partnerships.

“CNH Industrial is committed to further digitalizing modern agriculture, with the clear ambition to develop a comprehensive suite of digital and connectivity services to help our customers run their farming operations in a seamless and productive way,” said Hubertus Mühlhäuser, Chief Executive Officer, CNH Industrial. “The acquisition of AgDNA, is further evidence of our continuing investment in digital farming.”

This FMIS will be commercialized from Q4 2019 onwards, initially in North America, through the Case IH and New Holland Agriculture dealer networks. It enhances the agronomic feature-set capabilities of Case IH AFS Connect and New Holland MyPLM Connect and represents another step in bringing the brands’ dealer networks closer to their customers enhancing overall farming productivity through decision-making efficiencies.

This acquisition forms part of CNH Industrial’s long-term roadmap to enhance and extend its precision farming offering, in line with its commitment to delivering increasing digitalization and servitization in agriculture to add value for both customers and shareholders.

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

Sign up for corporate news alerts from the CNH Industrial Newsroom: 
bit.ly/media-cnhindustrial-subscribe

Media contacts:
                        
Laura Overall
Corporate Communications Manager
CNH Industrial                    
Tel. +44 (0)2077 660 338                           
E-mail: mediarelations@cnhind.com

Attachment

H Industrial to lead NIKOLA’s Series D round with $250 million investment. Parties announce strategic partnership to industrialize fuel-cell and battery electric Heavy-Duty Trucks for North America and Europe

London, September 3, 2019

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI), today announced its intention to enter into a strategic and exclusive Heavy-Duty Truck partnership with Nikola Corporation, based in Phoenix, Arizona, U.S.A., to accelerate industry transformation towards emission neutrality of Class 8 / Heavy-Duty Trucks in North America and Europe through the adoption of fuel-cell technology.

Nikola’s zero-emission Heavy Duty Trucks, powered by proprietary hydrogen fuel cell and battery technology, will be the first-to-production. The company’s disruptive business model foresees an industry-first ‘all-in’ lease rate, which includes vehicle, service, maintenance and fuel costs, providing long-term total cost of ownership certainty at or below diesel costs.

CNH Industrial will take a $250 million strategic stake in Nikola as the lead Series D investor, comprising $100 million cash and $150 million in services, such as product development, manufacturing engineering, and other technical assistance, as well as supply of certain key components to accelerate the production timeline of the Nikola TWO and Nikola TRE. Pre-money valuation was set at $3 billion. Nikola anticipates raising over $1 billion in the D round, granting approximately 25% ownership to new investors and business partners, including CNH Industrial.

IVECO and FPT Industrial, the commercial vehicle and powertrain brands of CNH Industrial respectively, will assist in engineering and manufacturing expertise to industrialize Nikola’s fuel-cell and battery electric trucks. The following vehicles will benefit from this partnership: the Nikola ONE, a NAFTA- compliant Class 8 sleeper truck; the Nikola TWO, a NAFTA-compliant Class 8 day-cab truck; and the Nikola TRE, a European compliant cab-over Heavy-Duty Truck.

Nikola will contribute technologies for a European Joint Venture with CNH Industrial that will include class-leading fuel-cell expertise, e-axles, inverters, independent suspension, on-board hydrogen fuel storage, over-the-air software update functionality, infotainment, vehicle controls, vehicle-to-station communication protocols, power electronics, and access to a hydrogen fueling network.

Fuel-cell technology is the logical next step to liquefied natural gas (LNG) powered engines as it builds on existing refueling networks, enabling local on-site production of hydrogen. FPT Industrial has been at the forefront of alternative propulsion solutions for over two decades, having produced some 50,000 natural gas-powered engines to date. IVECO is the absolute European leader in natural gas vehicles, with some 28,000 of its trucks and buses powered by FPT Industrial engines.

FPT Industrial and IVECO have been instrumental in the development and expansion of Europe’s natural gas refueling network, in addition to successfully introducing new powertrain technology. Following a similar path, Nikola is actively working with partners to develop the required hydrogen refueling infrastructure in North America and Europe.

Strategic near-term project milestones include the industrialization of the Nikola TWO fuel cell- powered Class 8 truck for the North American market, as well as the integration of IVECO S-Way truck technology into the battery-electric powered Nikola TRE cab-over model for both the North American and European markets. In the long-term, a European Joint Venture will cover both battery electric vehicles (BEV) and fuel-cell electric vehicles (FCEV) launched by Q4 2022. Nikola plans to leverage IVECO’s European sales, service and warranty channels to accelerate access to the European market.

“The increasing focus on the recognition that there needs to be fundamental reductions in automotive emissions is driving our industry to rapidly seek advanced technological solutions. IVECO is now ideally placed to offer customers an even wider range of transport solutions including natural gas, electric and fuel-cell powered vehicles,” said Hubertus Mühlhäuser, Chief Executive Officer, CNH Industrial. “Nikola’s choice of IVECO as its strategic partner is testament to our internationally recognized excellence in heavy duty trucks and alternative powertrain technologies.”

“The time has come to finally provide a zero-emission solution to the heavy-duty truck market. While other OEMs believe zero-emission solutions cannot happen in the timeframe regulators have mandated, Nikola, FPT Industrial and IVECO are proving that these timelines are not unreasonable,” said Trevor Milton, Chief Executive Officer, Nikola Corporation. “Nikola has the technology but needs a partner with a European network to achieve it in a timely manner. With CNH Industrial’s investment and partnership, we can now bring zero-emission trucks to Europe. It is exciting to see IVECO taking the lead in providing zero-emission solutions in Europe through its partnership with Nikola. By bringing CNH Industrial on board, we now have access to manufacturing know-how, purchasing power, validated truck parts, plant engineering and much more. Few will doubt our ability to commercialize a truck now.”

“Global climate change, geopolitical conflicts, future availability of fossil fuels and a self-aware circular economy all call for a fundamental change in how we operate,” added Gerrit Marx, President Commercial and Specialty Vehicles, CNH Industrial. “While today LNG delivers significantly lower well-to-wheel emissions, in the medium to long-term, fuel-cell and BEV technologies will deliver the ultimate goal of zero-emission trucking. With our LNG technology we have proven to be European disruptors, taking the lead in industry transformations including fuel supply and lifecycle ownership.”

A European press conference and fleet day will be jointly-hosted by Nikola Corporation, FPT Industrial and IVECO later this year to explain the partnership in greater detail.

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: http://www.cnhindustrial.com

Nikola Corporation designs and manufactures hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen stations. The company is bringing the nation’s most advanced semi-trucks to market with more than 14,000 trucks on preorder. Nikola is led by its visionary CEO Trevor Milton. The company is privately-held and headquartered in Arizona. For more information, visit www.nikolamotor.com.

Media contacts:
                        
CNH Industrial
Richard Gadeselli                                              Laura Overall
Corporate Communications                                Corporate Communications
Tel. +44 (0)2077 660 346                              Tel. +44 (0)2077 660 338

E-mail: mediarelations@cnhind.com

Nikola
Colleen Robar
Tel. +1.313.207.5960
E-mail: crobar@robarpr.com,

Attachment